HCP 15
Medical Oncologist · France · Senior consultant
Illustrative synthetic data for prototype demonstration — not real clinical findings.
Discussion summary
Broadly supportive; values consistency with prior clinical experience of the class.
Key themes
Pre / post perception
Overall perception shiftNo matched pre/post perception for this HCP
This conversation is not part of the matched pre/post perception sample, so a before-and-after comparison is not available. Their qualitative positions above still reflect what they said at congress.
KBQs discussed
Position against each predefined questionClinical significance of the primary endpoint
What is the expert consensus regarding the clinical significance of the study’s primary endpoint results?
“What matters is that the benefit looks clinically meaningful, not just statistically significant.”
Safety, tolerability and willingness to prescribe
How do HCP perceptions of the trial’s safety and tolerability profile impact their willingness to adopt and prescribe the treatment?
“The tolerability is manageable in my hands — I would prescribe this without much hesitation.”
Use in node-positive populations
What is the clinical consensus among HCPs regarding the use of CDK4/6 inhibitors in node-positive patient populations?
“My hesitation is cumulative tolerability across a long treatment course.”
Sequencing after adjuvant recurrence
How do clinicians approach treatment sequencing following recurrence on an adjuvant CDK4/6 inhibitor?
“If they responded well before and recurred late, I would not rule out re-challenge.”
Compelling nature of the primary endpoint
How compelling are the primary endpoint findings in driving prospective prescribers to select this treatment over existing options?
“This is the kind of result that changes how I would sequence treatment.”
Perception of safety and tolerability
How do experts perceive the safety and tolerability profile demonstrated in the trial?
“The profile is predictable and consistent with the class — nothing here surprises me.”